Literature DB >> 26715063

NRASQ61R immunohistochemistry: a new tool for mutational status screening in challenging melanoma samples.

Arnaud Uguen1,2,3, Matthieu Talagas2,3,4, Sebastian Costa2, Marc De Braekeleer1,3,5, Pascale Marcorelles2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26715063     DOI： 10.1038/modpathol.2015.78

Source DB:  PubMed          Journal:  Mod Pathol        ISSN： 0893-3952            Impact factor:   7.842


× No keyword cloud information.
  6 in total

1.  Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.

Authors:  Carlotta Petti; Alessandra Molla; Claudia Vegetti; Soldano Ferrone; Andrea Anichini; Marialuisa Sensi
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

2.  Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.

Authors:  Daniela Massi; Lisa Simi; Elisa Sensi; Gianna Baroni; Gongda Xue; Cristian Scatena; Adele Caldarella; Pamela Pinzani; Gabriella Fontanini; Alessandra Carobbio; Carmelo Urso; Mario Mandalà
Journal:  Mod Pathol       Date:  2014-10-24       Impact factor: 7.842

3.  Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.

Authors:  Jonathan C Dudley; Grzegorz T Gurda; Li-Hui Tseng; Derek A Anderson; Guoli Chen; Janis M Taube; Christopher D Gocke; James R Eshleman; Ming-Tseh Lin
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

4.  Lymph node metastases of melanoma: challenges for BRAF mutation detection.

Authors:  Guoli Chen; Jonathan Dudley; Li-Hui Tseng; Kirstin Smith; Grzegorz T Gurda; Christopher D Gocke; James R Eshleman; Ming-Tseh Lin
Journal:  Hum Pathol       Date:  2014-10-07       Impact factor: 3.466

5.  Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.

Authors:  Klaus J Busam; Cyrus Hedvat; Melissa Pulitzer; Andreas von Deimling; Achim A Jungbluth
Journal:  Am J Surg Pathol       Date:  2013-03       Impact factor: 6.394

6.  Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma.

Authors:  M Sensi; G Nicolini; C Petti; I Bersani; F Lozupone; A Molla; C Vegetti; D Nonaka; R Mortarini; G Parmiani; S Fais; A Anichini
Journal:  Oncogene       Date:  2006-02-06       Impact factor: 9.867
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.